William Blair initiated coverage of Pieris Pharmaceuticals (NASDAQ:PIRS) with an “outperform” rating. The stock closed $7.46 on Jan. 16.Read More
Roth Capital Partners reinitiated coverage of Pieris Pharmaceuticals (NASDAQ:PIRS) with a “buy” rating and $6 price target. The stock closed at $1.70 on Thursday.
“We believe the company’s anticalin platform has broad potential for the long term and that the multiple partners, broad pipeline and flexibility of the platform provide investors with the potential for multiple catalysts along with partner-based non-dilutive funding,” writes analyst Joseph Pantginis.Read More